Compare Biogen Inc (BIIB) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Riot Platforms Inc — how do they compare? Biogen Inc trades at $195.45 (market cap $28.34B), while Riot Platforms Inc trades at $19.46 (market cap $7.64B). The key difference: Biogen Inc is far larger — about 3.7× Riot Platforms Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | RIOT | |
|---|---|---|
Market Cap | $28.34B | $7.64B |
Sector | Health | Technology |
52-Week High | $216.63 | $28.67 |
52-Week Low | $122.68 | $11.03 |
Enterprise Value | $30.62B | $8.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
RIOT stock trades at $20.19, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $663.18 million in 2025, with a negative net income margin of -132.76%, though revenue reached $647.44 million. Analyst consensus remains strongly bullish with a $27.86 price target, supported by 17 buy ratings. Recent news highlights volatility amid broader crypto stock trends and a strategic pivot toward high-performance computing.
The outlook is mixed: strong analyst support and a strategic shift to data centers offer upside, but persistent losses, negative cash flow from operations, and sensitivity to Bitcoin market swings pose significant risks. Investors should weigh the high valuation multiples against the company's unprofitability and execution challenges in its expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
